The largest database of trusted experimental protocols

Nmri nu mice

Manufactured by Janvier Labs
Sourced in France

NMRI/nu mice are a laboratory mouse strain commonly used in biomedical research. They are characterized by a lack of thymus, resulting in a deficiency of T cells and a compromised immune system. This strain is often used as an experimental model for studying various diseases and evaluating therapeutic interventions.

Automatically generated - may contain errors

5 protocols using nmri nu mice

1

Xenograft Tumorigenicity Assay in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
To further characterize the NCH93 cells, their tumorigenicity was tested in a xenograft mouse model. Animal experiments were approved by the Regierungspraesidium Karlsruhe (35-9185.81/G-193/17). For the in vivo tumorigenicity study, 1 × 106 cells suspended in 100 µL Matrigel (Cat. # 356237, Corning, New York, NY, USA) were injected subcutaneously into the flank regions of 5–6 week-old female NMRI/nu mice (Janvier Laboratory, Le Genest-Saint-Isle, France). Tumor growth was measured every second day by a caliper. Animals were sacrificed seven weeks after tumor cell injection reaching a tumor volume of approximately 1000 mm³.
+ Open protocol
+ Expand
2

Xenogeneic and Syngeneic Tumor Models

Check if the same lab product or an alternative is used in the 5 most similar protocols
Tumors were generated by subcutaneous injections in the back left leg for RT ballistic purposes. Xenogeneic PC3 tumors were induced in 6–8 weeks old male NMRInu mice (Janvier, Saint Berthevin, France) with 2 × 106 cells in 50 µL of medium without FBS 21 days before RT. Syngeneic LLC tumors were induced in 6–8 weeks old female C57BL/6 mice (Janvier) with 106 cells 10 days before RT. Each group was composed of 7–10 animals per fractionation schedule, and each experiment was performed twice. Tumors were measured with a caliper and volume was estimated with the V = 0.5 × a × b2 formula [33 (link)]. For immunohistochemistry, animals were sacrificed and tumors were excised 14 days after the first dose of RT. For tumor growth, animals were euthanized when the tumor reached 2000 mm3. All experiments were carried out in accordance with the European Council Directive 2010/63/UE and approved by the local Animal Care and Use Committee (C2EA-06).
+ Open protocol
+ Expand
3

In Vivo Mouse Xenograft Models

Check if the same lab product or an alternative is used in the 5 most similar protocols
Female immunodeficient NMRI-nu mice (6-weeks-old) were used for in vivo experiments (Janvier Labs), except for prostate cancer cell lines (PC-3, LNCaP, DU-145), where males have been used. For experiments with Patient Derived Xenograft LPS80T3 (obtained by direct transplantation of a poorly differentiated human grade 3 retroperitoneal malignant fibrous histiocytoma) and PAC-120 (obtained from a hormone-dependent prostate primary adenocarcinoma) models, 8-weeks-old Hsd:Athymic nude-FOXn1 female and 5-weeks-old Hsd:Athymic nude-FOXn1 male were used, respectively (XenTech). Mice were maintained under pathogen-free conditions in the animal facility. All animal experiments were carried out in compliance with French and European laws and regulations (European Directive 2010/63 EU). The local institutional animal ethics board and French Ministère de la Recherche approved all mouse experiments.
+ Open protocol
+ Expand
4

Subcutaneous Tumor Modeling and Ponatinib Treatment

Check if the same lab product or an alternative is used in the 5 most similar protocols
All experiments were done in accordance with the regulations of animal protection and approved by the Regierungspraesidium Karlsruhe, Germany. Five to six-week-old female NMRI/nu mice (Janvier Laboratory, Le Genest-Saint-Isle, France) received subcutaneous injections into the right flank with 4 × 106 NCH93 cells in 100 µL medium and 100 µL Matrigel (Corning, San Diego, CA, USA). Tumor volume was measured daily by using a digital caliper and it was calculated using the following equation: Volume = (Length × Width2)/2 [38 (link)], where length represents the longest tumor diameter and width represents the perpendicular tumor diameter. When the tumor volume reached 200 mm3, mice were randomly divided into DMSO and ponatinib treatment groups. The dosage of 10 mg per kg bodyweight of ponatinib was administered intraperitoneally daily. The weight of the mice was measured on a daily basis. On day 21, mice were sacrificed, and blood was drawn and immediately sent to the central laboratory of University Hospital Heidelberg for further analysis. Excised tumors were weighed and photographed. Tumor tissues were snap-frozen and stored at −80 °C until further processing.
+ Open protocol
+ Expand
5

Conditional Ablation of cDC1 in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
8–10-wk-old female C57BL/6 and NMRI-nu mice were purchased from Janvier Laboratories. Few experiments were performed on male mice. Xcr1Cre-mTFP1 and Rosa26LSL−DTA (B6.129P2-Gt(ROSA)26Sortm1(DTA)Lky/J) were previously described (Voehringer et al, 2008 (link); Wohn et al, 2020 (link)). Xcr1Cre-mTFP1 mice were crossed to Rosa26lsl−DTA mice in which Cre-mediated excision of a loxP-flanked transcriptional STOP element triggers the expression of diphtheria toxin fragment A (DTA), and results in the constitutive ablation of cDC1 in Xcr1DTA. Mice were housed under a standard 12-h:12-h light–dark cycle with ad libitum access to food and non-acid water, 22°C ± 1°C, and 45–60% humidity, and were maintained under specific pathogen-free conditions at the animal facility of the Centre d’Immunologie de Marseille-Luminy (F1305510). Experimentations were authorized by the Ethical Committee for Animal Experimentation (#30566–2021032215496999 v2; APAFIS). Collaborative experiments using Xcr1DTA mice (Wohn et al, 2020 (link)) were performed in B. Malissen’s laboratory (#26488–2020070612584424 v2; APAFIS).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!